GlassScriptPhysician profile
Raymond Mai
NPI 1215399456
$13,803.80
in general payments reported to CMS, 2019-2025
41 companies · $4,212 in 2025
The $4,212 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $434 · 2021: $951 · 2022: $1,404 · 2023: $4,046 · 2024: $2,368 · 2025: $4,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,227 · Travel and Lodging: $1,366 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,226.90 |
| Travel and Lodging | $1,366.31 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $2,172.81 | 2022-2024 | Pascal, Sapien 3 Ultra Resilia, Evoque |
| Aop Health US, LLC | $1,517.49 | 2025 | Rapiblyk |
| Amgen INC. | $854.92 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $816.05 | 2021-2025 | Farxiga, Lokelma, Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $801.41 | 2022-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $799.50 | 2019-2025 | |
| Pfizer INC. | $642.13 | 2022-2025 | |
| Abbott Laboratories | $627.28 | 2019-2025 | Triclip, Amplatzer Talisman, Cardiomems |
| E.R. Squibb & Sons, L.L.C. | $574.26 | 2022-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $550.72 | 2023-2025 | Verquvo, Capvaxive |
| Abiomed | $526.37 | 2020-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $523.16 | 2019-2025 | Lifevest |
| Esperion Therapeutics, INC. | $426.32 | 2023-2025 | Nexletol |
| Medtronic Vascular, INC. | $415.28 | 2019-2020 | |
| Inari Medical, INC. | $402.04 | 2021-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Mai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.